LSE · AOTI.L
AOTI, Inc.
£1.33+£0.01 (+0.76%)
AOTI, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.67% below the high.
Loading market information…
LSE · HVO.L · GBp
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 04:27 PM UTC. Cached market data; not a live quote.
One-year closing-price history · GBp. Historical prices are not a forecast.
hVIVO plc’s quoted price sits in the lower half of its reported 52-week range, 45.45% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
hVIVO plc’s forward annual dividend is £0.00 per share, paid annual. The forward yield is 3.33% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
hVIVO plc’s next earnings report is currently expected on Apr 14, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow hVIVO plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
hVIVO plc (HVO) operates as a premier full-service Contract Research Organisation (CRO) focused on early-phase clinical development, globally recognized as the leader in human challenge trials. The company provides a complete spectrum of clinical development services to a wide-ranging and growing client base, which includes seven of the world's ten largest biopharmaceutical companies. A key specialisation for hVIVO is orchestrating human challenge trials across numerous infectious and respiratory diseases, utilising its advanced, London-based quarantine facility, the largest of its kind globally. Additionally, the company offers extensive virology and immunology laboratory services through its hLAB division. Through its German subsidiary, CRS, hVIVO manages a 120-bed capacity across sites in Mannheim and Kiel, delivering early-phase clinical trial expertise, including first-in-human and proof-of-concept studies. Its other subsidiary, Venn Life Sciences, contributes to the biopharma sector by providing specialist early drug development consulting and biometry services. The Group collectively offers integrated drug development solutions, covering stages from preclinical research up to Phase II trials, supported by patient recruitment via FluCamp. Moreover, its five clinical sites facilitate outpatient Phase II and III trials, ensuring a streamlined and effective transition from drug discovery to late-stage development.
Latest available per-share figures in GBP. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:43 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| £0.01 |
| £27.30M-4.89% vs estimate |
| Q1 2023 | Apr 25, 2023 | -£0.00 | £31.70M+3.26% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
£1.33+£0.01 (+0.76%)
AOTI, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.67% below the high.
£1.90£0.00 (0.0%)
Kooth plc’s quoted price sits in the upper half of its reported 52-week range, 6.65% below the high.
£0.10+£0.00 (+2.63%)
Ondine Biomedical Inc.’s quoted price sits in the upper half of its reported 52-week range, 37.1% below the high.
£0.11+£0.00 (+1.11%)
Creo Medical Limited’s quoted price sits in the lower half of its reported 52-week range, 38.51% below the high.
£0.07-£0.00 (-2.26%)
Poolbeg Pharma PLC’s quoted price sits in the upper half of its reported 52-week range, 32.64% below the high.
£6.80+£0.07 (+1.04%)
Hemogenyx Pharmaceuticals Plc’s quoted price sits in the lower half of its reported 52-week range, 44.26% below the high.
£0.83£0.00 (0.0%)
Arecor Therapeutics plc’s quoted price sits in the upper half of its reported 52-week range, 13.16% below the high.
£0.04+£0.00 (+6.12%)
ImmuPharma PLC’s quoted price sits in the lower half of its reported 52-week range, 67.09% below the high.
